TD Asset Management’s Immuneering IMRX Stock Holding History

TD Asset Management’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$325K	Sell	65,196 -29,144	-31%	-$147K	﹤0.01%	1200
2026 Q1	$497K	Sell	94,340 -23,506	-20%	-$121K	﹤0.01%	1171
2025 Q4	$775K	Sell	117,846 -27,334	-19%	-$175K	﹤0.01%	1129
2025 Q3	$1.02M	Buy	+145,180	New	+$753K	﹤0.01%	1087
2025 Q2	–	Sell	-71,066	Closed	-$108K	–	1223
2025 Q1	$108K	Sell	71,066 -79,810	-53%	-$145K	﹤0.01%	1208
2024 Q4	$332K	Hold	150,876	–	–	﹤0.01%	1205
2024 Q3	$401K	Hold	150,876	–	–	﹤0.01%	1319
2024 Q2	$193K	Hold	150,876	–	–	﹤0.01%	1342
2024 Q1	$436K	Sell	150,876 -47,000	-24%	-$263K	﹤0.01%	1315
2023 Q4	$1.45M	Sell	197,876 -86,600	-30%	-$577K	﹤0.01%	1097
2023 Q3	$2.18M	Buy	284,476 +142,238	+100%	+$1.31M	﹤0.01%	931
2023 Q2	$1.44M	Sell	142,238 -1,865	-1%	-$17.9K	﹤0.01%	1042
2023 Q1	$1.4M	Sell	144,103 -2,611	-2%	-$14.8K	﹤0.01%	1076
2022 Q4	$712K	Sell	146,714 -947	-0.6%	-$8.39K	﹤0.01%	1209
2022 Q3	$1.94M	Hold	147,661	–	–	﹤0.01%	1013
2022 Q2	$799K	Buy	147,661 +26,460	+22%	+$141K	﹤0.01%	1217
2022 Q1	$784K	Buy	121,201 +86,905	+253%	+$835K	﹤0.01%	1273
2021 Q4	$555K	Hold	34,296	–	–	﹤0.01%	1369
2021 Q3	$911K	Buy	+34,296	New	+$922K	﹤0.01%	1274

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

TD Asset Management's IMRX Position: Q2 2026 in Review

TD Asset Management reduced its Immuneering (IMRX) stake by 31% in Q2 2026, selling an estimated $147K and leaving 65,196 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #1200.

TD Asset Management first reported a position in IMRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.18M in Q3 2023. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

TD Asset Management held 65,196 shares of Immuneering worth $325K as of Q2 2026.
TD Asset Management sold 29,144 Immuneering shares in Q2 2026, an estimated $147K.
Immuneering made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1200 holding.
TD Asset Management first reported a position in Immuneering in Q3 2021 and has held it in 19 quarters since.
TD Asset Management's Immuneering position peaked at $2.18M in Q3 2023.
112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.